FDA BLA · BLA761336
ANKTIVA
nogapendekin alfa inbakicept-pmln
Sponsor: ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
BLA761336
TYPE
BLA
ORIGINAL APPROVAL
2024-04-22
LATEST ACTION
2026-10-14
ROUTE
INTRAVESICAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
ANKTIVAPrescription
nogapendekin alfa inbakicept-pmln 400mcg/0.4 mL · SOLUTION · INTRAVESICAL
Approval history
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →